Pulsed field ablation for atrial fibrillation in patients with heart failure: insight from the ATHENA registry
Authors:
- Marco SchiavoneMarco Schiavone
- Francesco SolimeneFSFrancesco Solimene
- Antonio Dello RussoARAntonio Dello Russo
- Stefano BianchiSBStefano Bianchi
- Saverio IacopinoSaverio Iacopino
- Maurizio MalacridaMMMaurizio Malacrida
- Sakis ThemistoclakisSTSakis Themistoclakis
- Matteo BertiniMatteo Bertini
- Ilaria MeynetIMIlaria Meynet
- Massimo MoltrasioMMMassimo Moltrasio
- Vincenzo SchillaciVSVincenzo Schillaci
Open Access
- 17 March 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Abstract
Aims: Data on pulsed-field ablation (PFA) for atrial fibrillation (AF) in patients with heart failure (HF) are limited. To evaluate clinical outcomes of PFA in patients with AF and HF, stratified by HF subtype. Methods and Results: Consecutive patients undergoing first-time pentaspline PFA within the ATHENA registry were analyzed. Patients were stratified into three groups: no HF, HF with preserved ejection fraction (HFpEF, LVEF ≥50%), and HF with mildly reduced or reduced EF (HFmrEF/rEF, LVEF 30 s after a 2-month blanking period. AAD use was left to physician discretion. Among 1,224 patients included (68.5% with paroxysmal AF and 31.5% with persistent AF), 176 (14.4%) had HF: 40 (3.3%) with HFpEF and 136 (11.1%) with HFmrEF/rEF. The Kaplan-Meier estimated freedom from any atrial arrhythmias at 1-year follow-up was 79.9%, with higher rate in the no-HF group (81.0%) vs the HF group (73.3%, HR = 1.5, 95% CI: 1.1–2.1, P = 0.0133). Considering separately paroxysmal and persistent AF form, paroxysmal AF patients with no sign of HF showed significantly higher freedom from atrial arrhythmias (82.2%) than patients with HF (68.6%, 2.0, 1.3–3.1, P = 0.0028), while no differences were found in patients with persistent AF (77.9% vs 76.4%, 1.1, 0.7–1.7, P = 0.7065). Conclusion: PFA with the pentaspline catheter appears to be an effective treatment for AF in patients with HF. Freedom from AF and atrial arrhythmias post-PFA was highest in patients with paroxysmal AF and no history of HF, with no significant differences observed in persistent AF patients. Clinical Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/Identifier: NCT05617456.Keywords
This publication has 30 references indexed in Scilit:
- Benefits of Pulsed-Field Ablation in Patients With Atrial Fibrillation and Heart FailureJACC: Clinical Electrophysiology, 2024
- Safety and Effectiveness of Pulsed Field Ablation for Atrial Fibrillation in Patients With Heart FailureJACC: Clinical Electrophysiology, 2024
- Pulsed-field vs cryoballoon vs radiofrequency ablation: Outcomes after pulmonary vein isolation in patients with persistent atrial fibrillationHeart Rhythm, 2024
- Progression of Atrial Fibrillation after Cryoablation or Drug TherapyNew England Journal of Medicine, 2023
- Pulsed field ablation as first-line “efficient” rhythm control for atrial fibrillation complicated with heart failure: proof-of-conceptJournal of Interventional Cardiac Electrophysiology, 2022
- Outcomes of patients with heart failure with preserved ejection fraction undergoing catheter ablation of atrial fibrillationHeart Rhythm O2, 2022
- Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart FailureJACC, 2018
- Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fractionHeart Rhythm, 2018
- Catheter Ablation for Atrial Fibrillation with Heart FailureNew England Journal of Medicine, 2018
- Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic DysfunctionJACC, 2017